Resource Allocation for Different Types of Vaccines against COVID-19:

Tradeoffs and Synergies between Efficacy and Reach

Daniel Kim

H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of

Technology, Atlanta, GA 30332, email: dkim608@gatech.edu

Pelin Pekgün

Moore School of Business, University of South Carolina, Columbia, SC 29208,

email: pelin.pekgun@moore.sc.edu

İnci Yildirim

Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale School of

Medicine and Yale Institute of Global Health, 1 Church Street, New Haven, CT 06510,

email: inci.yildirim@yale.edu

Pınar Keskinocak

H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of

Technology, Atlanta, GA 30332, email: pinar@isye.gatech.edu

Corresponding Author:
Pınar Keskinocak
H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of
Technology, Atlanta, GA 30332, email: pinar@isye.gatech.edu

Abstract:

Objective: During the COVID-19 pandemic, multiple vaccine candidates were developed in
record time. The primary decision for a vaccine-ordering decision-maker then becomes how to
allocate limited resources between different types of vaccines. One may expect that available
resources should be favored towards a vaccine with high efficacy if it can be distributed as
widely as any other vaccine. However, if a high efficacy vaccine consumes more resources than
a vaccine with lower efficacy due to distributional challenges, the decision is no longer trivial as
a widespread vaccination is necessary to reach herd immunity.
9
10 *Methods*: We adapt a Susceptible-Infected-Recovered-Deceased (SIR-D) model with vaccination
11 and simulate the level of *infection attack rate* (IAR) under different resource consumption ratios
12 between two vaccine types with different resource allocation decisions.
13
Results: We find that when there are limited resources, allocating resources entirely to a vaccine
with high efficacy that becomes available earlier than a vaccine with lower efficacy that becomes
available later does not always lead to a lower IAR, particularly if the former can immunize less
than a range of 5.9% to 6.4% of the population (with the selected study parameters) before the
latter becomes available. Sensitivity analyses show that this result stays robust under different
efficacy levels for the higher efficacy vaccine.
20
Conclusions: Our results show that the reach of a vaccine to be distributed widely under limited
resources is a key factor to achieve low IAR levels, even though the vaccine may be of higher
efficacy and may become available earlier than others. Manufacturing a novel vaccine lacking a
fully developed suitable infrastructure for its effective distribution and storage may impact the
potential benefits of the immunization program. Understanding the tradeoffs between efficacy
and reach is critical for resource allocation decisions between different vaccine types to
maximize the improvement in health outcomes.

Declaration of interests
2
3   ☐ The authors declare that they have no known competing financial interests or personal
4   relationships that could have appeared to influence the work reported in this paper.
5
6   ☒The authors declare the following financial interests/personal relationships which may be considered
7   as potential competing interests:
8

Dr İnci Yildirim reported being a member of the mRNA-1273 Study Group. Dr. Yildirim has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micron.

Dr Pinar Keskinocak received funding to her institution from Merck to conduct non-clinical research.

The funders played no role in the study design, data collection, analysis, interpretation, or in writing the manuscript.

Keywords: resource allocation; vaccination; disease modeling; COVID-19; vaccine efficacy

Preference for colors in Table 3, Figure 1, Figure 2, Figure 3 and Figure 4: Online Only

Introduction

In December 2019, the outbreak of the novel coronavirus (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), was first detected in Wuhan, China. As of mid-January 2021, approximately 96 million cases have been reported worldwide including resource limited populations [1]. An efficacious vaccine is considered essential in addition to mitigation techniques such as wearing a mask or physical distancing (keeping a 6-feet distance away from others).

Coalition for Epidemic Preparedness and Innovation (CEPI) reported in September 2020 that there were 321 COVID-19 vaccine candidates [2]. As of January 2021, 68 of those candidates are in Phase 1-3 clinical trials and seven have been approved and used throughout the world [3]. The U.S. government and Biomedical Advanced Research and Development Authority (BARDA) have funded and secured a large quantity of vaccine doses that were enough to vaccinate the entire U.S. population from major vaccine manufacturers, three of which have reported achievements from their Phase 3 clinical trials in developing vaccines against COVID-19 without serious side-effects [4, 5]. Pfizer & BioNTech and Moderna announced mRNA-based vaccines with average efficacies of 95% and 94.5%, respectively, while AstraZeneca announced its adenovirus-vectored vaccine with average efficacy of 70% [6, 7]. All of these efficacies meet the minimum efficacy threshold established by the U.S. Food and Drug Administration (FDA). Pfizer and Moderna received emergency use authorizations (EUA) from FDA on December 11, 2020 and December 18, 2020, respectively, and other manufacturers are still seeking for EUA as

of January 2021. The chief adviser to Operation Warp Speed (OWS) also stated that Johnson &

Johnson could have enough data to seek for EUA from FDA in January 2021 [8].

Despite the high efficacies, mRNA-based COVID-19 vaccine candidates may face

critical supply-chain challenges from distribution to storage since they require cold temperatures

to maintain their aptness. For instance, Pfizer & BioNTech and Moderna's vaccines need to be

stored at about minus 70 Celsius degrees and minus 20 Celsius degrees, respectively [9].

Advanced cold-chain logistics and storage solutions are not available in many regions, which can

impede mass vaccine distribution efforts while maintaining quality. On the other hand,

adenovirus-vector COVID-19 vaccine candidates, despite their lower efficacy than mRNA-based

vaccines, can be stored at 2-8 Celsius degrees, which is the temperature seasonal flu vaccine

requires, and therefore, their mass distribution is expected to be easier [9, 10]. The reach of a

vaccine, the ability to distribute it widely, which can be impeded by supply-chain challenges, can

impact vaccine coverage and the proportion of the population who have access to the vaccine

jeopardizing infection control and achievement of herd immunity through vaccination.

Having an efficacious vaccine approved for use will be of little use if not enough people

can have access to the vaccine. Both having the efficacious vaccine and having a high

vaccination coverage will be essential. With these insights, governments, vaccine manufacturers

and researchers have been working on developing effective COVID-19 vaccine ordering and

distribution strategies. Specifically, vaccine prioritization—which group of people should be

prioritized for vaccination—has gained notable attention [11]. However, there has not been

enough attention on which vaccine, among different candidates, should be prioritized for

ordering and administering, which would have an implication on the allocation of limited

available resources. Considering the high efficacy of mRNA-based vaccines and lower efficacy

of other types of vaccines, should a vaccine-ordering decision maker always favor an mRNA-

based vaccine despite its potential logistics and storage challenges? Or should lower efficacy

vaccines, which can be distributed widely using existing vaccine logistics and storage

infrastructure, be favored?

The main goal of this study is to understand how to allocate limited resources between

different types of vaccines considering the tradeoffs and synergies between efficacy vs. reach.

Specifically, we seek to answer the following question: "Is it worth ordering a vaccine with low-

efficacy that becomes available later if it can be distributed more widely than a vaccine with

high-efficacy that becomes available sooner but consumes more resources for distribution or

storage?" Using a modified Susceptible-Infected-Recovered-Deceased (SIR-D) model, we

simulate the health outcomes, *infection attack rate* (IAR) and the *peak of daily infections* (i.e.,

the highest percentage of the population who get newly infected on a single day), under different

resource consumption ratios between two types of vaccines with different resource allocation

decisions. The results of this study are aimed to guide decision makers in vaccine ordering and

distribution with their resource planning decisions during a pandemic when multiple types of

vaccines become available.

Methods

We consider two types of vaccines that become available at different points of time. The

vaccine with high efficacy (denoted vaccine-H, hereafter) becomes available sooner than the

vaccine with lower efficacy (denoted vaccine-L, hereafter). We assume that both vaccine types

require a single dose and an individual who receives an *effective* vaccine of either type becomes

immunized immediately. In our model, there is a fixed and uniform number of resources (K)

available each day. We consider the resource allocation decision for each vaccine type ($a_H, a_L \in$

$[0,1], a_H + a_L = 1$), assuming that it cannot be modified once it is committed. Thus, the resource

allocation decision directly defines the quantity of each vaccine type that could be administered

each day. We normalize the resource consumption requirements of each type of vaccine such

that for each unit of resource, while one person can receive one unit of vaccine-L, only a

"fraction of one person (λ)" can receive one unit of vaccine-H. We denote this ratio as the

resource consumption ratio ($\lambda < 1$), which indicates how widely vaccine-H can be distributed

relative to vaccine-L given limited available resources. We set a range of 0.1 to 0.7 for the

resource consumption ratio in our simulations. We present the daily quantity of each vaccine

type that can be administered as a function of the allocation decision and the resource

consumption ratio in Table 1.

Table 1: Daily resources allocated to each vaccine and available quantity of each vaccine

Available Vaccine	Vaccine-H		Vaccine-L	
	Allocated Resources	Daily Quantity	Allocated Resources	Daily Quantity
None	0	0	0	0
Vaccine-H	$a_H K$	$a_H \lambda K$	0	0
Vaccine-H and L	$a_H K$	$a_H \lambda K$	$a_L K$	$a_L K$

$a_H, a_L \in [0,1]$: Resource allocation to vaccine-H and vaccine-L, respectively
λ: Resource consumption ratio
K: Daily resources

In our main study, we set the efficacy of vaccine-H at 90% and vaccine-L at 70% and

examine different efficacy levels of vaccine-H, keeping efficacy of vaccine-L at 70%, within the

range of 85% to 95% in the sensitivity analyses reported in Supplemental Materials. These

vaccine efficacies meet the minimum COVID-19 vaccine efficacy threshold (=50%) established

by the FDA and are motivated from the currently projected efficacies of the COVID-19 vaccine

candidates. Note that if we were to assume that both vaccine types became available at the same

time, the decision would become trivial: choose the resource allocation such that the number of

immunized individuals on each day is maximized. Thus, we choose a non-trivial setting where

the high efficacy vaccine becomes available earlier; vaccine-H and vaccine-L become available

on days 209 and 239 from the start of the pandemic, respectively. We also examine different

days of availability for vaccine-L, keeping that of vaccine-H on day 209, within the range of 239

to 259 in the sensitivity analyses reported in Supplemental Materials. We assume that during the

period when only vaccine-H is available (from day 209 to 238), any unused daily resources are

lost.

In addition to these key parameters of interest, we choose epidemiological parameter values,

fixed throughout the simulations, based on the SARS-CoV-2 characteristics. You et al. (2020)

report that the infectious period of COVID-19 is estimated to be an average of 13.96 days with a

standard deviation of 5.20 days [12]. Hence, we set the recovery rate of the disease to be 0.0716.

According to Johns Hopkins Coronavirus Research Center, the case fatality ratio (CFR), which is

the ratio of reported deaths to reported cases, is approximately 2% in the United States [13].

Considering this, we set the death rate of the disease to be 0.0015, at which CFR is

approximately 2.04% in our simulations. Severity of a disease is often described by reproduction

number (R_t) by epidemiologists. The Centers for Disease and Prevention (CDC) has developed

COVID-19 Pandemic Planning Scenarios and suggested three different basic reproduction

numbers: 2.0, 2.5 and 4.0 [14]. We use the reproduction number of 2.0 due to a few reasons,

even though the reproduction number of 2.5 is recommended by the CDC as the best parameter

value. In particular, facing a pandemic with a highly infectious disease, such as in the case of

COVID-19, many non-pharmaceutical interventions, such as mask mandates and physical

distancing, are often implemented, which can contribute to a considerable decrease in the

reproduction number [15]. While we do not model such non-pharmaceutical interventions in our

simulations, we instead consider a lower reproduction number. In addition, we also compare the

number of daily infections and cumulative infections through day 208 (before the distribution of

vaccine-H) in our simulations to the COVID-19 datasets from [16], which estimate and forecast

the number of infected people including those who are not tested or confirmed. Assuming that

both vaccine types become available for distribution before the peak of daily infections, our

simulation results under a reproduction number of 2.0 are aligned with the estimates in these

public datasets. Thus, we conclude that a reproduction number of 2.0 is a more realistic choice

for our simulations. To set the reproduction number at 2.0, considering the recovery rate and

death rate, we set the disease-transmission rate to be 0.1462.

We adapt an SIR-D compartmental model to portray the trajectory of an infectious disease

and the number of infections averted by a vaccine. SIR-D model is a simplified and deterministic

mathematical model of infectious diseases and classifies people into different compartments

based on their health status at each time point. Transitions among different compartments are

governed by ordinary differential equations given the epidemiological and vaccine parameters

defined previously. *Susceptible* population enters the *Infected* compartment once they make

infectious contacts with the infected population and become infectious themselves. Infected

population either recovers from the disease and enters the *Recovered* compartment or die and

enter the *Deceased* state.

We add four new compartments to the SIR-D model. Susceptible population who receives

vaccine *i* (= H or L) enters either '*Vaccinated-Susceptible-i*' or '*Immunized-i*' compartment.

Those who receive *effective* vaccine *i* are protected from the virus and enter the *Immunized-i*

compartment. Those who receive vaccine *i* but do not develop enough antibodies to fight off

infection (i.e., *ineffective* vaccine) enter the '*Vaccinated-Susceptible-i′*' compartment. We make

several assumptions in the model:

• Vaccinated-Susceptible-H and Vaccinated-Susceptible-L populations are unaware of

their susceptibility and do not get vaccinated again.

• Vaccinated-Susceptible-H and Vaccinated-Susceptible-L populations have the same

capability of being infected as (unvaccinated) susceptible population.

• Decision makers can identify which individual is in which compartment. For instance, if

an individual receives vaccine-H, the decision maker knows whether the individual has

received effective vaccine or ineffective vaccine.

• The entire quantity of a vaccine is administered each day unless there is no longer a

susceptible population or the simulation ends.

We run the simulation using R software with a population size of 10.6 million (approximate

population of the state of Georgia [17]). We initialize the simulation such that 0.000001% of this

population is infected and the rest are susceptible on day 1. The decision maker initially acquires

the total supply of resources equivalent to the population size and plans to use the resources

uniformly over 180 days (i.e., daily resource $K =$ 10.6 million / 180). The simulation is run over

a one-year planning horizon with varying resource allocations between the two vaccine types

$(a_H, a_L; a_H + a_L = 1)$ within the range of 0 to 1 with a discrete step size of 0.1, and varying

resource consumption ratios within the range of 0.1 to 0.7 with a discrete step size of 0.02. We

evaluate the impact of a resource allocation policy using IAR as the main health outcome.

Results

Our simulations show that if no vaccines are introduced, approximately 79.84% of the

population is infected with the disease. In addition, about 1.29% of the population is *newly*

infected at the peak of the daily infections on day 249 from the start of the pandemic, while the

number of infected individuals is the highest on day 259 with 15.61% of the population infected.

In the simulations with the vaccines, vaccine-H and vaccine-L are introduced on days 209 and

239, respectively, which is before the peak of daily infections. On day 208 (i.e., one day before

vaccine-H becomes available), the cumulative number of cases is at approximately 4.15% of the

population, of whom 2.03% actively spread the disease to the susceptible population.

Table 2 shows the estimated percentage of the population that become immunized each day

as a result of receiving *effective* vaccination, the quantity of which varies under different

resource consumption ratios in the range of 0.34 to 0.4 with different resource allocation

decisions. As the proportion of resources allocated to vaccine-H decreases linearly, the

proportion of daily immunized population with vaccine-H decreases linearly, while that with

vaccine-L increases linearly.

Table 2: Percentage of daily immunized population under different resource allocation decisions
and consumption ratios

Fraction of Resources Allocated to Vaccine H and L (a_H, a_L)	Immunized with Vaccine-H (%) Resource Consumption Ratio (λ)				Immunized with Vaccine-L (%)	Total Daily Immunized Population (Day 239 – 365)[*]
	0.34	0.36	0.38	0.4		
(1, 0)	0.17	0.18	0.19	0.20	0	[0.170, 0.200]
(0.9, 0.1)	0.153	0.162	0.171	0.18	0.039	[0.192, 0.219]
(0.8, 0.2)	0.136	0.144	0.152	0.16	0.078	[0.214, 0.238]
(0.7, 0.3)	0.119	0.126	0.133	0.14	0.117	[0.236, 0.257]
(0.6, 0.4)	0.102	0.108	0.114	0.12	0.156	[0.258, 0.276]
(0.5, 0.5)	0.085	0.090	0.095	0.10	0.194	[0.279, 0.294]
(0.4, 0.6)	0.068	0.072	0.076	0.08	0.233	[0.301, 0.313]
(0.3, 0.7)	0.051	0.054	0.057	0.06	0.272	[0.323, 0.332]
(0.2, 0.8)	0.034	0.036	0.038	0.04	0.311	[0.345, 0.351]
(0.1, 0.9)	0.017	0.018	0.019	0.02	0.350	[0.367, 0.370]
(0, 1)	0	0	0	0	0.389	0.389

Vaccine-H and Vaccine-L become available on days 209 and 239, respectively.
When the vaccine of a given type is not available, no susceptible population becomes immunized with that vaccine.

172   Table 3 shows the estimated IAR (rounded to four significant figures) under different

173 resource consumption ratios in the range of 0.34 to 0.4 with different resource allocation

174 decisions.

---

[*] Total daily immunized population varies depending on the resource consumption ratio

Figure 1 depicts the results in Table 3 on a two-dimensional graph with the allocation

decision as an independent variable and IAR as a dependent variable. Figure 2 presents the IAR

on a three-dimensional graph with varying resource consumption ratios and resource allocation

decisions. Figure 3 and Figure 4 present the number of daily infections and cumulative infections

with respect to the population over time, respectively. When the resource consumption ratio is at

most 0.34, allocating the resources entirely to vaccine-L (i.e., $a_H = 0, a_L = 1$) minimizes IAR.

On the other hand, allocating the resources entirely to vaccine-H (i.e., $a_H = 1, a_L = 0$)

minimizes IAR only when the resource consumption ratio is at least 0.4. When the resource

consumption ratio is between 0.34 and 0.4, one vaccine type is not favored entirely, and a

decision on how much to allocate the resources to each vaccine type needs to be made.

Table 3: Infection attack rate under different resource allocation decisions and consumption
ratios

Fraction of Resources Allocated to Vaccine-H and L (a_H, a_L)	Resource Consumption Ratio (λ)			
	0.34	0.36	0.38	0.4
(1, 0)	64.74	63.92	63.11	62.31
(0.9, 0.1)	64.49	63.77	63.05	62.34
(0.8, 0.2)	64.27	63.64	63.01	62.39
(0.7, 0.3)	64.07	63.53	62.99	62.46
(0.6, 0.4)	63.91	63.46	63.00	62.55
(0.5, 0.5)	63.78	63.41	63.04	62.67
(0.4, 0.6)	63.68	63.38	63.09	62.80
(0.3, 0.7)	63.60	63.38	63.17	62.95
(0.2, 0.8)	63.55	63.40	63.26	63.12
(0.1, 0.9)	63.52	63.45	63.38	63.31
(0, 1)	63.51	63.51	63.51	63.51

Figure 1: Infection attack rate under different resource allocation decisions (with different
resource consumption ratios $\lambda = 0.32, 0.34, 0.36, 0.38$ and 0.40 from top to bottom). When the
resource consumption ratio is at most 0.34, $a_H = 0$ (equivalently, $a_L = 1$) minimizes IAR, and
when it is at least 0.40, $a_H = 1$ (equivalently, $a_L = 0$) minimizes IAR.

Figure 2: Contour plot of infection attack rate under different resource allocation decisions (a_H)
and consumption ratios (λ). When comparing two different resource consumption ratios that are
both less than or equal to 0.34 (i.e., $\lambda_1 < \lambda_2 \leq 0.34$), the one with λ_1 can achieve a smaller IAR
with a lower a_H than the one with λ_2 and a higher a_H.

Figure 3: Daily new infections under different resource consumption ratios (λ) and allocation
decisions (a_H and a_L). Three scenarios are considered: (red) $-\lambda = 0.34$, $a_H = 1$, (green) $-\lambda =$
0.40, $a_H = 1$, and (blue) $- a_L = 1$ (or equivalently, $a_H = 0$, where the resource consumption
ratio has no impact on the simulation). The peak of daily infections is highest when $a_L = 1$.

203
204

205　*Figure 4: Infection attack rate under different resource allocation decisions and consumption*
206　*ratios over time. Same parameter values are used for the scenarios as in Figure 3. The lowest*
207　*IAR among the three scenarios is achieved when $\lambda = 0.4$ and $a_H = 1$, followed by when $a_L = 1$*
208　*and when $\lambda = 0.34$ and $a_H = 1$.*

Discussion

In this study, we simulate the trajectory of an infectious disease using a modified SIR-D model when two types of vaccines with different efficacies and resource consumption rates were introduced at different points in the horizon during a pandemic. We demonstrate that the reach of a vaccine to be distributed widely under limited resources is a key factor to achieve low IAR levels, even though the vaccine may be of higher efficacy and may become available earlier than others. A recent study modeled a similar setting with various vaccine efficacies, daily administered quantities, and reproduction numbers for the case of a single type of vaccine (either prophylactic vaccine, disease-modifying vaccine, or a composite of the two); thus, resource allocation decisions between multiple types of vaccines, as in our study, were not considered [18]. The study showed that the wider reach of a vaccine could result in significant reductions in total infections and deaths, which is consistent with our study's findings. However, we consider two types of prophylactic vaccines—vaccine-H and vaccine-L—whose daily quantities distributed are determined by resource allocation decisions and resource consumption ratios. In addition, the vaccine with high efficacy (vaccine-H) is introduced earlier in our study than the vaccine with lower efficacy (vaccine-L), consistent with the vaccine development setting during the COVID-19 pandemic. Pfizer and Moderna's mRNA-based vaccines with expected efficacy of at least 90%, an example of vaccine-H in our model, became the first vaccine against COVID-19 available for distribution in the United States, while other vaccine candidates, such as AstraZeneca's adenovirus-vectored vaccine with expected efficacy of 70%, an example of vaccine-L in our model, is anticipated to be distributed later. The mRNA-based vaccines face potential logistics and storage challenges due to the requirement of extremely low temperatures, whereas the adenovirus-vectored vaccines do not. Our study captures the impact of these

challenges and thus, the reach of the vaccines through the resource consumption ratio parameter,

and shows that allocating more resources to vaccine-H that becomes available earlier than

vaccine-L does not always guarantee better health outcomes if vaccine-H cannot be distributed

more widely than vaccine-L.

Reducing the number of infections is of paramount importance during a pandemic, which is

possible via various non-pharmaceutical and pharmaceutical interventions, including

prophylactic vaccines. The decline in new infections can lead to a decline in the effective

reproduction number and, potentially, even the eradication of the pandemic. Hence, the

implementation of effective vaccines as early as possible is of the essence. In addition, the

number of individuals who can be vaccinated by either type of vaccine each day throughout the

epidemic (both before and after the peak of daily infections) critically affects the potential

benefits of a vaccine upon its implementation. One may intuitively expect that allocating

resources primarily towards vaccine-H, which becomes available sooner, can minimize IAR.

However, our simulations indicate that this may not always be true. In particular, allocating more

resources to vaccine-H, when it is highly resource-intensive, leads to fewer individuals being

vaccinated and a worse overall IAR. Even when vaccine-L becomes available after the peak of

daily infections, this continues to hold.

Accordingly, identifying what percent of the population can be immunized with vaccine-H

before vaccine-L becomes available plays a key role in the resource allocation decision between

the two types of vaccines. Since we assume that the resource allocation decisions are made

before either vaccine type is introduced with fixed epidemiological parameter values and vaccine

attributes, as shown in Table 2, the allocation decisions can aim to either 1) immunize more

people early on with vaccine-H in lieu of utilizing larger quantities of vaccine-L once it becomes

available, or 2) immunize fewer people early on with vaccine-H and more people later utilizing a

larger quantity of vaccine-L once it becomes available. If the first strategy is chosen, the decision

maker needs to increase the resource allocation to vaccine-H, and if the second strategy is

chosen, the opposite action needs to be taken. The tradeoff is that in the first strategy where more

resources are allocated to the resource-intensive but effective vaccine-H, more people can be

vaccinated with vaccine-H before vaccine-L becomes available (days 209-238). However, since

the allocation decision is made at the beginning of the horizon and cannot be modified

afterwards, this then implies fewer resources allocated to the less resource-intensive vaccine-L,

which can reach a wider population. The result is that not many people can be vaccinated with

vaccine-L once it becomes available (days 239-365), as compared to the second strategy where

more resources are allocated to vaccine-L from the beginning. Thus, in order for the first strategy

to be preferable from a health outcome perspective, vaccine-H should be able to immunize a

sufficient number of people early on (days 209-238) to exceed the health benefits from a larger

vaccine coverage in later periods (days 239-365) using the second strategy. Our results show that

if the resource consumption ratio is at least 0.4 and, consequently, at least 6% of the population

can be immunized with vaccine-H before vaccine-L becomes available, then the first strategy is

preferred, and vaccine-H should be fully allocated all available resources (i.e., $a_H = 1$). This

observation is driven by the fact that a sufficient number of individuals need to be immunized

before the peak of daily infections is reached so that fewer people become infected and spread

the disease. When we examine the number of daily infections in our simulations, the case of

$a_H = 1$ lowers the peak of daily infections if the resource consumption ratio is at least 0.16,

which is a lot lower than the 0.4 threshold for this case to hold. On the other hand, if at most

5.1% of the population could be immunized with vaccine-H before vaccine-L becomes available

(which occurs when the resource consumption ratio is at most 0.34, i.e., vaccine-H is highly

resource-intensive), then the second strategy is preferred and vaccine-L should be fully allocated

all available resources (i.e., $a_L = 1$). As shown in Figure 3 and Figure 4, even though the peak of

daily infections is higher when $a_L = 1$ compared to the peak when $\lambda = 0.34$ and $a_H = 1$, the

former peak occurs only a day before the latter peak, and the number of daily infections drops

faster when $a_L = 1$, which leads overall to a lower IAR. These results remain robust under

different efficacy levels of vaccine-H from 85% to 95% and different days of availability for

vaccine-L from 239 to 259, as shown in Supplemental Materials, despite different resource

consumption ratio thresholds based on the efficacy of vaccine-H and the availability day for

vaccine-L, respectively. The different resource consumption ratio thresholds in Supplemental

Materials indicate that allocating resources entirely to vaccine-H does not lead to a lower IAR, if

it can immunize less than a range of 5.9% to 6.4% of the population before vaccine-L becomes

available.

Our study also shows that an incorrect resource allocation, or a resource allocation that

neglects the extent of resource consumption differences between the two vaccine types, can have

a major impact on the total number of infections. When vaccine-H is highly resource-intensive

(the resource consumption ratio is at most 0.34), a linear increase in the allocated resources to

vaccine-H results in an increase in the IAR at a faster rate. For example, when the resource

consumption ratio is exactly 0.34, the IAR under $a_L = 1$ is about 1.22% lower than the IAR

under $a_H = 1$. For a total population size of 10.6 million as in our model, this corresponds to

approximately 130,000 infections that could have been averted by allocating all resources to

vaccine-L. As the resource consumption ratio declines and vaccine-H becomes even more

resource-intensive than vaccine-L, the impact on IAR can even be more drastic, with differences

in IAR due to the two allocation policies increasing at a faster rate. For example, when the

resource consumption ratio is 0.24, the difference in IAR is 5.44%, while when the ratio further

declines to 0.14, the difference in IAR increases to 9.85%, corresponding to an increase from

about 570,000 infections to 1.04 million infections that could have been averted by allocating all

resources to the lower-efficacy but less resource-intensive vaccine-L. On the other hand, when

the resource consumption ratio is at least 0.4, a linear increase in the allocation of resources to

vaccine-H results in a lower IAR at a faster rate. For example, when the resource consumption

ratio is 0.4, 0.5 and 0.6, the IAR under $a_H = 1$ is 1.20%, 5.07% and 8.71% lower than the IAR

under $a_L = 1$, respectively. Thus, when vaccine-H is not as highly resource-intensive, allocation

of resources towards the high efficacy vaccine which becomes available earlier can lead to lower

IAR levels.

The resource and resource consumption can be interpreted in many ways depending on the

context. For instance, the resource could correspond to trained healthcare workers, where each

vaccine administration site needs to identify how many trained health-care workers are required

to administer vaccine-H if it requires more stringent quality monitoring and administration

processes than vaccine-L. Alternatively, the resource may refer to a fixed monetary budget,

where the resource consumption ratio would imply differences in the cost of production,

distribution, storage or deployment of vaccine-H relative to that of vaccine-L. For instance, in

September 2020, the U.S. Department of Health and Human Services (HHS) and the CDC

provided $200 million to jurisdictions for COVID-19 vaccine preparedness, which could be used

to support vaccine providers and healthcare workforce, open new vaccine administration sites

and purchase personal protective equipment [19]. A third alternative interpretation for resource

could be related to storage requirements. An administration site needs to determine how much of

its storage space (and/or available funds to purchase equipment) should be allocated to ultra-cold

freezers to store vaccine-H vs. refrigerators to store vaccine-L. An ultra-cold freezer may be able

to store a lower quantity of vaccine-H to preserve appropriate temperatures, relative to a

refrigerator's capacity for vaccine-L, or in order to hold the same quantity of vaccines, it may

take up a larger space due to its physical structure.

If a decision maker has the means of increasing the resource consumption ratio by either

reducing the resource requirements of vaccine-H relative to vaccine-L or increasing its

capabilities to cover more individuals with vaccine-H given the resource requirements, this is

always beneficial as it increases the daily number of vaccines that can be administered. However,

increasing the resource consumption ratio may imply different levels of complexity depending

on how it is defined in a given context. For example, if we refer back to the example of the ultra-

cold freezers and refrigerators, increasing the resource consumption ratio could be very costly

and difficult since each ultra-cold freezer costs more than $10,000. Many hospitals, especially

those in rural areas, cannot afford these expensive freezers as nearly half of U.S. rural hospitals

have been running deficits since early 2020, stated by the chief executive of the National Rural

Health Association [20]. In addition, the CDC's interim COVID-19 Playbook, lastly updated on

October 29, 2020, also states that jurisdictions are advised not to purchase ultra-cold storage

equipment [21]. These scenarios would correspond to the low values of the resource

consumption ratios in our models, where the decision maker may not have much room to change

those but treat as given. In such a case, the decision maker can still minimize IAR by allocating

more of its available resources to the lower efficacy vaccine given its potential wider reach,

rather than putting a significant effort into trying to incrementally increase the resource

consumption ratio and allocate resources to vaccine-H. In our simulations, allocating all

resources to vaccine-H with a resource consumption ratio of 0.36 gives an IAR of 63.92%. For a

slightly smaller ratio of 0.34, the decision maker can still achieve an IAR lower than 63.92%

with a reduction in the resource allocation to vaccine-H ($a_1 \leq 0.6$). Hence, a decision maker can

still achieve the same level of IAR under a slightly higher resource consumption ratio by

allocating more resources to vaccine-L. This also implies that if some individuals must be

vaccinated early (e.g., frontline workers) but the resource consumption of vaccine-H is too high,

the decision maker should procure the smallest amount of vaccine-H that is enough to cover

those individuals, which still results in a smaller IAR than investing the entire resources into

vaccine-H and/or putting effort to increase the resource consumption ratio slightly.

We also acknowledge some limitations of this study. First, our modified SIR-D model

does not fully capture the potential trajectory of an infectious disease over its lifetime. There

could be additional stages (compartments), such as *asymptomatic infected* individuals who

spread the disease with a different transmission rate or *symptomatic infected* individuals who are

either quarantined or hospitalized such that they no longer spread the virus. Second,

implementation of non-pharmaceutical interventions often separates conforming individuals

from the susceptible population temporarily. Individuals who decide to stop conforming to the

interventions may re-enter the susceptible populations during a pandemic, as considered in [22].

Third, a virus may mutate and change the reproduction number over time. Fourth, while we

assume a homogeneous population, each individual may show different characteristics to build

antibodies when vaccinated or to recover from the virus, depending on factors such as

demographics. Fifth, we model all vaccinations in an immediate deployment rather than a phased

rollout. Even if one receives an effective vaccine, it may still take several days to fully build

antibodies and fight off the infection. Lastly, our model assumes that both vaccine types require

a single dose. Most of the current vaccine candidates against COVID-19, both mRNA-based and

adenovirus-vector-based, require two doses with three to four weeks apart application to provide

the most protection. Since the individuals who receive the first shot experience minimal

protection and could still get infected before the second shot, it would be worthwhile to simulate

a two-dose vaccine scenario. In this scenario, identifying the trade-off between the resource

consumption ratio and efficacy may be even more critical since the vaccines would consume

more resources.

Overall, our results suggest that allocating limited resources towards a prophylactic

vaccine with high efficacy that becomes available earlier than a prophylactic vaccine with lower

efficacy may not always result in increased benefits of a vaccine upon its implementation,

especially if the latter can be distributed more widely. In fact, this may result in a significant

deterioration in the infection attack rates if the high-efficacy vaccine is highly resource intensive,

relative to the low-efficacy one, such that only a few people can be vaccinated each day.

Therefore, identifying the resource consumption requirements of each vaccine type as a function

of their efficacy levels, timelines and disease characteristics, is critical for resource allocation

decisions, as there is a clear threshold for which vaccine type should be favored, and a significant

improvement in health outcomes can be achieved. Manufacturing an mRNA-based vaccine is

based on a new vaccine development technology, which is expected to be one of the prime

methods in the future. Therefore, building a suitable infrastructure for effective distribution and

storage of mRNA-based vaccines, considering the tradeoffs and synergies between efficacy and

reach, is critical. We hope that this study can provide guidance to decision makers in their

resource planning for different vaccine types to better prepare for future pandemics.

References

1. World Health Organization. *WHO Coronavirus Disease (COVID-19) Dashboard*. 2020 [cited 2021 Jan 22]; Available from: https://covid19.who.int.

2. Coalition for Epidemic Preparedness and Innovation. *321 vaccine candidates against COVID-19 now in development*. 2020 [cited 2020 Dec. 14]; Available from: https://cepi.net/news_cepi/321-vaccine-candidates-against-covid-19-now-in-development/.

3. Zimmer, C., J. Corum, and S.-L. Wee. *Coronavirus Vaccine Tracker*. New York Times 2020 Jan 9 [cited 2020 Jan. 22]; Available from: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.

4. U.S. Department of Health and Human Services. *U.S. Government Engages Pfizer to Produce Millions of Doses of COVID-19 Vaccine*. 2020 July 22; Available from: https://www.hhs.gov/about/news/2020/07/22/us-government-engages-pfizer-produce-millions-doses-covid-19-vaccine.html.

5. U.S. Department of Health and Human Services. *Trump Administration's Operation Warp Speed Accelerates AstraZeneca COVID-19 to be Available Beginning in October*. 2020; Available from: https://www.hhs.gov/about/news/2020/05/21/trump-administration-accelerates-astrazeneca-covid-19-vaccine-to-be-available-beginning-in-october.html.

6. Pfizer. *Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase-3 Study*. 2020 [cited 2020 Dec 14]; Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against.

7. AstraZeneca. *AZD1222 Vaccine Met Primary Efficacy Endpoint in Preventing COVID-19*. 2020 [cited 2020 Dec 14]; Available from: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/azd1222hlr.html.

8. Roubein, R. *2 more vaccine developers could seek FDA's green light by February*. Politico 2020 [cited 2020 Dec 14]; Available from: https://www.politico.com/news/2020/12/14/more-vaccine-developers-fda-approval-445194.

9. Holm, M. and G. Poland, *Critical Aspects of Packaging, Storage, Preparation, and Administration of mRNA and Adenovirus-vectored COVID-19 Vaccines for Optimal Efficacy.* Vaccine, 2020.

10. Centers for Disease Control and Prevention. *Influenza A (H1N1) 2009 Monovalent Vaccine Storage, Preparation, Handling Q&A*. 2010 [cited 2020 Dec 14]; Available from: https://www.cdc.gov/h1n1flu/vaccination/storage_handling_qa.htm.

11. Hezam, I.M., et al., *COVID-19 Vaccine: A Neutrosophic MCDM Approach for Determining the Priority Groups.* Results in Physics, 2020: p. 103654.

12. You, C., et al., *Estimation of the time-varying reproduction number of COVID-19 outbreak in China.* International Journal of Hygiene and Environmental Health, 2020: p. 113555.

435   13.   Dong, E., H. Du, and L. Gardner, *An interactive web-based dashboard to track COVID-19*
436   *in real time.* The Lancet infectious diseases, 2020. **20**(5): p. 533-534.

437   14.   Centers for Disease Control and Prevention. *COVID-19 Pandemic Planning Scenarios*
438   2020 [cited 2020 Dec 14]; Available from: https://www.cdc.gov/coronavirus/2019-
439   ncov/hcp/planning-scenarios.html.

440   15.   Li, Y., et al., *The temporal association of introducing and lifting non-pharmaceutical*
441   *interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling*
442   *study across 131 countries.* The Lancet Infectious Diseases, 2020.

443   16.   Worldometer. *COVID-19 Projections*. 2020 [cited 2020 Dec 14]; Available from:
444   https://covid19.healthdata.org/united-states-of-america/georgia?view=total-
445   deaths&tab=trend.

446   17.   U.S. Census Bureau. *QuickFacts: Georgia*. 2019 [cited 2021 Jan. 11]; Available from:
447   https://www.census.gov/quickfacts/GA.

448   18.   Paltiel, A.D., et al., *Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over*
449   *Efficacy: Study examines how definitions and thresholds of vaccine efficacy, coupled with*
450   *different levels of implementation effectiveness and background epidemic severity,*
451   *translate into outcomes.* Health Affairs, 2020: p. 10.1377/hlthaff. 2020.02054.

452   19.   Centers for Disease Control and Prevention. *Administration Announces $200 million*
453   *from CDC to Jurisdictions for COVID-19 Vaccine Preparedness*. 2020 [cited 2020 Dec 14];
454   Available from: https://www.cdc.gov/media/releases/2020/p0924-200-million-
455   jurisdictions-covid-19-preparedness.html.

456   20.   Goldhill, O. *'We're being left behind': Rural hospitals can't afford ultra-cold freezers to*
457   *store the leading Covid-19 vaccine*. 2020 [cited 2020 Dec 14]; Available from:
458   https://www.statnews.com/2020/11/11/rural-hospitals-cant-afford-freezers-to-store-
459   pfizer-covid19-vaccine/.

460   21.   Centers for Disease Control and Prevention. *COVID-19 Vaccination Program Interim*
461   *Playbook for Jurisdiction Operations. Version 2.0*. 2020 [cited 2020 Dec 14]; Available
462   from: https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19-Vaccination-
463   Program-Interim_Playbook.pdf.

464   22.   Cooper, I., A. Mondal, and C.G. Antonopoulos, *A SIR model assumption for the spread of*
465   *COVID-19 in different communities.* Chaos, Solitons & Fractals, 2020. **139**: p. 110057.

1   **Supplemental Materials**
2
3   Supplemental Exhibit 1: Identification of resource consumption ratio that favors vaccine-H and vaccine-L for the entire allocation of
4   resources under different efficacies of vaccine-H

Vaccine-H Efficacy (%)	Vaccine-L			Vaccine-H		
	Resource Consumption Ratio[*]	IAR when $a_H = 1$[†]	Percentage of Early-Immunized Population[‡]	Resource Consumption Ratio[§]	IAR when $a_H = 1$[†]	Percentage of Early-Immunized Population
85	0.36	64.72	5.10	0.42	62.43	5.95
86	0.34	65.35	4.87	0.42	62.25	6.02
87	0.34	65.20	4.93	0.42	62.06	6.09
88	0.34	65.04	4.98	0.42	61.88	6.16
89	0.34	64.89	5.04	0.40	62.49	5.93
90	0.34	64.74	5.10	0.40	62.31	6.00
91	0.32	65.42	4.85	0.40	62.14	6.07
92	0.32	65.28	4.91	0.40	61.97	6.13
93	0.32	65.13	4.96	0.40	61.80	6.20
94	0.32	64.99	5.01	0.38	62.45	5.95
95	0.32	64.85	5.07	0.38	62.29	6.02

[*] Under any lower resource consumption ratio, vaccine-L receives the entire allocation.

[†] IAR under the specified resource consumption ratio (When $a_L = 1$, IAR is fixed at 63.51% regardless of the resource consumption ratio).

[‡] Percentage of the population who become immunized with vaccine-H between days 209 and 238 (i.e., before vaccine-L becomes available) under the specified resource consumption ratio

[§] Under any higher resource consumption ratio, vaccine-H receives the entire allocation.

Supplemental Exhibit 2: Identification of resource consumption ratio that favors vaccine-H and vaccine-L for the entire allocation of resources under different days of availability for vaccine-L

Vaccine-L Available Time	Vaccine-L				Vaccine-H		
	Resource Consumption Ratio††	IAR $(a_H = 1, a_L = 1)$‡‡	Percentage of Early-Immunized Population§§		Resource Consumption Ratio***	IAR $(a_H = 1, a_L = 1)$	Percentage of Early-Immunized Population
239	0.34	(64.74, 63.51)	5.10		0.40	(62.31, 63.51)	6.00
244	0.28	(67.24, 65.54)	4.90		0.36	(63.92, 65.54)	6.30
249	0.24	(68.95, 67.43)	4.80		0.32	(65.57, 67.43)	6.40
254	0.20	(70.69, 69.17)	4.50		0.28	(67.24, 69.17)	6.30
259	0.16	(72.46, 70.76)	4.00		0.24	(68.95, 70.76)	6.00

†† Under any lower resource consumption ratio, vaccine-L receives the entire allocation.
‡‡ IAR under the specified resource consumption ratio
§§ Percentage of the population who become immunized with vaccine-H before vaccine-L becomes available under the specified resource consumption ratio
*** Under any higher resource consumption ratio, vaccine-H receives the entire allocation.